| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | n/a | n/a |
| Intrinsic value (DCF) | n/a | |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company pioneering innovative therapies for liver diseases, with a primary focus on non-alcoholic steatohepatitis (NASH). The company’s lead candidate, Aramchol, is an oral SCD1 modulator currently in Phase III trials for NASH in overweight or obese patients with pre-diabetes or type 2 diabetes. Galmed is also evaluating Aramchol in a Phase IIa trial for HIV-associated fatty liver disease. Additionally, the company is developing Amilo-5MER, a synthetic peptide with potential therapeutic applications. Galmed has forged strategic collaborations, including a partnership with Gannex Pharma to explore combination therapies and a licensing deal with Samil Pharma for Aramchol’s commercialization in South Korea. Headquartered in Tel Aviv, Israel, Galmed operates in the high-growth NASH market, which lacks FDA-approved therapies, positioning it as a potential disruptor in liver disease treatment.
Galmed Pharmaceuticals presents a high-risk, high-reward investment opportunity due to its focus on the underserved NASH market. The company’s lead candidate, Aramchol, has shown promise in clinical trials, but its success hinges on Phase III data and eventual regulatory approval. With no revenue and consistent operating losses, Galmed remains highly speculative. However, its low market capitalization (~$3.1M) and strategic partnerships could make it an attractive target for acquisition if Aramchol demonstrates efficacy. Investors should closely monitor clinical trial progress and funding runway, as the company will likely require additional capital to advance its pipeline.
Galmed Pharmaceuticals competes in the crowded NASH therapeutics space, where multiple companies are vying to bring the first approved treatment to market. Its competitive edge lies in Aramchol’s unique mechanism of action (SCD1 inhibition) and oral administration, which could offer advantages over injectable competitors. However, the company faces significant challenges, including competing against well-funded rivals like Madrigal Pharmaceuticals (MDGL) and Intercept Pharmaceuticals (ICPT), which have advanced late-stage candidates. Galmed’s small size and limited financial resources constrain its ability to independently commercialize Aramchol, making partnerships critical. The collaboration with Gannex Pharma to explore combination therapies could enhance Aramchol’s differentiation. Galmed’s focus on specific patient subgroups (e.g., NASH with pre-diabetes) may help in targeted clinical development but could also limit market potential. The lack of revenue and dependence on a single lead candidate heighten investment risk, though positive trial data could dramatically alter the company’s valuation.